Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)
Chart Events
Performance Outlook
| Previous Close | 37.09 |
| Open | 37.09 |
| Bid | 38.94 x 0 |
| Ask | 38.95 x 0 |
| Day's Range | 36.86 - 39.00 |
| 52 Week Range | 27.00 - 66.66 |
| Volume | |
| Avg. Volume | 54,230,682 |
| Market Cap | 249.061B |
| Beta (5Y Monthly) | 0.46 |
| PE Ratio (TTM) | 39.65 |
| EPS (TTM) | 0.98 |
| Earnings Date | Apr 18, 2022 - Apr 22, 2022 |
| Forward Dividend & Yield | 0.17 (0.56%) |
| Ex-Dividend Date | Jun 10, 2021 |
| 1y Target Est | 52.59 |
- Bloomberg
The Unsung Winners and Biggest Losers of China's Rocky Markets in 2021
(Bloomberg) -- In a year that’s seen China’s “common prosperity” agenda roil global equity markets, the nation’s policies also created a greater divide between stock winners and losers at home.Most Read from BloombergWHO Downplays Threat of Covid-19 Variant Found in FranceU.S. Logs Record 1 Million Virus Cases With Data DelayOmicron Cases Are Hitting Highs, But New Data Put End in SightHong Kong Scraps Flights, Shuts Bars, Gyms on Omicron ThreatHong Kong Vaccine Surge Sees Majority Pick Sinovac
- Benzinga
BeyondSpring Inks Plinabulin Agreement In Greater China
BeyondSpring Inc (NASDAQ: BYSI) and Jiangsu Hengrui Pharmaceuticals Co Ltd have entered into an exclusive commercialization and co-development agreement for plinabulin in Greater China. In combination with G-CSF, Plinabulin is currently under FDA Priority Review and the China National Medical Products Administration for the prevention of chemotherapy-induced neutropenia (CIN). Related Content: BeyondSpring Stock Is Up More than 300%: What You Need To Know? BeyondSpring's 58%-owned subsidiary, Wa
